Phase II trial of recombinant tumor necrosis factor in disseminated malignant melanoma

E. R. Feldman, E. T. Creagan, Daniel J Schaid, D. L. Ahmann

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Twenty-one patients with disseminated malignant melanoma received recombinant tumor necrosis factor (TNF), 150 μg/m2 intravenously on days 1- 5 every 2 weeks for four cycles and then every 3 weeks. Recombinant TNF produced no meaningful palliation. One patient (5%) attained an objective response of nodal, but not visceral, disease, which lasted 3 weeks. The median time to progression was 4 weeks. The median survival was 7.7 months. Ninety percent of patients developed mild to severe cytokine 'flu.' Ten percent developed significant hepatic toxicity (AST > 3 times normal). As a single agent, recombinant TNF is not likely to palliate disseminated malignant melanoma. However, combinations of recombinant TNF and cytotoxic or immune modulatory agents, particularly gamma interferon, may merit further investigation.

Original languageEnglish (US)
Pages (from-to)256-259
Number of pages4
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume15
Issue number3
StatePublished - 1992

Fingerprint

Melanoma
Tumor Necrosis Factor-alpha
Interferon-gamma
Cytokines
Survival
Liver

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Phase II trial of recombinant tumor necrosis factor in disseminated malignant melanoma. / Feldman, E. R.; Creagan, E. T.; Schaid, Daniel J; Ahmann, D. L.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 15, No. 3, 1992, p. 256-259.

Research output: Contribution to journalArticle

@article{2dbeb8345c6f4800885aa97f2ee53b16,
title = "Phase II trial of recombinant tumor necrosis factor in disseminated malignant melanoma",
abstract = "Twenty-one patients with disseminated malignant melanoma received recombinant tumor necrosis factor (TNF), 150 μg/m2 intravenously on days 1- 5 every 2 weeks for four cycles and then every 3 weeks. Recombinant TNF produced no meaningful palliation. One patient (5{\%}) attained an objective response of nodal, but not visceral, disease, which lasted 3 weeks. The median time to progression was 4 weeks. The median survival was 7.7 months. Ninety percent of patients developed mild to severe cytokine 'flu.' Ten percent developed significant hepatic toxicity (AST > 3 times normal). As a single agent, recombinant TNF is not likely to palliate disseminated malignant melanoma. However, combinations of recombinant TNF and cytotoxic or immune modulatory agents, particularly gamma interferon, may merit further investigation.",
author = "Feldman, {E. R.} and Creagan, {E. T.} and Schaid, {Daniel J} and Ahmann, {D. L.}",
year = "1992",
language = "English (US)",
volume = "15",
pages = "256--259",
journal = "American Journal of Clinical Oncology: Cancer Clinical Trials",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Phase II trial of recombinant tumor necrosis factor in disseminated malignant melanoma

AU - Feldman, E. R.

AU - Creagan, E. T.

AU - Schaid, Daniel J

AU - Ahmann, D. L.

PY - 1992

Y1 - 1992

N2 - Twenty-one patients with disseminated malignant melanoma received recombinant tumor necrosis factor (TNF), 150 μg/m2 intravenously on days 1- 5 every 2 weeks for four cycles and then every 3 weeks. Recombinant TNF produced no meaningful palliation. One patient (5%) attained an objective response of nodal, but not visceral, disease, which lasted 3 weeks. The median time to progression was 4 weeks. The median survival was 7.7 months. Ninety percent of patients developed mild to severe cytokine 'flu.' Ten percent developed significant hepatic toxicity (AST > 3 times normal). As a single agent, recombinant TNF is not likely to palliate disseminated malignant melanoma. However, combinations of recombinant TNF and cytotoxic or immune modulatory agents, particularly gamma interferon, may merit further investigation.

AB - Twenty-one patients with disseminated malignant melanoma received recombinant tumor necrosis factor (TNF), 150 μg/m2 intravenously on days 1- 5 every 2 weeks for four cycles and then every 3 weeks. Recombinant TNF produced no meaningful palliation. One patient (5%) attained an objective response of nodal, but not visceral, disease, which lasted 3 weeks. The median time to progression was 4 weeks. The median survival was 7.7 months. Ninety percent of patients developed mild to severe cytokine 'flu.' Ten percent developed significant hepatic toxicity (AST > 3 times normal). As a single agent, recombinant TNF is not likely to palliate disseminated malignant melanoma. However, combinations of recombinant TNF and cytotoxic or immune modulatory agents, particularly gamma interferon, may merit further investigation.

UR - http://www.scopus.com/inward/record.url?scp=0026773669&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026773669&partnerID=8YFLogxK

M3 - Article

VL - 15

SP - 256

EP - 259

JO - American Journal of Clinical Oncology: Cancer Clinical Trials

JF - American Journal of Clinical Oncology: Cancer Clinical Trials

SN - 0277-3732

IS - 3

ER -